Leukemia: Clinical Trials

544 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

544 terminated. 544 Phase 1, 189 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1544Terminated 544
Phase 2189Terminated 189

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 544 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
Antigen-specific T cells CAR-T/CTL and DCvac - T-Cell Acute Lymphoblastic Leukemia
Phase 1TerminatedShenzhen Geno-Immune Medical Institute102026-06-012026-11-03
Multiple CAR-T Cell Therapy Targeting AML
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedShenzhen Geno-Immune Medical Institute102025-08-012026-11-02
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies
Phase 1 / Phase 2TerminatedShenzhen Geno-Immune Medical Institute1002025-08-012026-10-30
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
CD19 t-haNK - B-ALL, Leukemia
Phase 1TerminatedImmunityBio, Inc.42025-04-112026-08-19
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
Phase 1 / Phase 2TerminatedServier Bio-Innovation LLC132025-02-252026-03-30
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult
Phase 1 / Phase 2TerminatedBlueSphere Bio, Inc22025-02-042026-09-10
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
BL-M11D1 - Relapsed/Refractory Acute Myeloid Leukemia
Phase 1TerminatedSystImmune Inc.522024-12-192026-09-24
A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
AUR104 - Select Relapsed/Refractory Lymphoid Malignancies
Phase 1TerminatedAurigene Discovery Technologies Limited92024-12-122026-04-17
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Venetoclax, Azacitidine, Donor Lymphocyte Infusion - Acute Myeloid Leukemia
Phase 1TerminatedAntonio M Jimenez Jimenez22024-12-042026-07-13
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Luveltamab tazevibulin - Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2TerminatedSutro Biopharma, Inc.12024-12-042026-10-13
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
Phase 1TerminatedRoswell Park Cancer Institute12024-11-262025-08-03
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory
Phase 1 / Phase 2TerminatedCentre Leon Berard12024-09-112025-02-20
Study of Tazemetostat in Lymphoid Malignancies
Tazemetostat - T-cell Lymphoma
Phase 1TerminatedUniversity of Alabama at Birmingham62024-09-052026-04-17
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedSanofi72024-08-132026-10-19
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
BMS-986497, Azacitidine, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 1TerminatedBristol-Myers Squibb342024-05-292026-10-01
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CB-012 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Phase 1TerminatedCaribou Biosciences, Inc.122024-02-082025-06-11
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
VCAR33 - Leukemia, Myeloid, Acute
Phase 1 / Phase 2TerminatedVor Biopharma382023-12-112025-07-29
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs - Acute Myeloid Leukemia
Phase 1TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins72023-11-202026-06-25
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)32023-11-142025-12-02
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ABBV-787 - Acute Myeloid Leukemia
Phase 1TerminatedAbbVie362023-11-132025-03-06

Showing 20 of 544. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (289)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (154)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (132)  ·  Myelodysplastic Syndromes (107)  ·  Lymphoma, Non-Hodgkin (89)  ·  Recurrence (73)  ·  Lymphoma (66)  ·  Lymphoma, Large B-Cell, Diffuse (64)  ·  Lymphoma, Mantle-Cell (61)  ·  Lymphoma, Follicular (59)  ·  Burkitt Lymphoma (51)  ·  Lymphoma, B-Cell, Marginal Zone (49)  ·  Multiple Myeloma (48)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (42)

Broader conditions

Hemic and Lymphatic Diseases (544)  ·  Neoplasms by Histologic Type (541)  ·  Hematologic Diseases (538)  ·  Neoplasms (511)  ·  Leukemia, Myeloid (318)  ·  Immune System Diseases (290)  ·  Immunoproliferative Disorders (287)  ·  Lymphoproliferative Disorders (282)  ·  Pathological Conditions, Signs and Symptoms (281)  ·  Lymphatic Diseases (280)  ·  Pathologic Processes (280)  ·  Disease Attributes (275)  ·  Leukemia, Lymphoid (247)  ·  Chronic Disease (228)

Interventions

Cytarabine (55)  ·  Azacitidine (47)  ·  Cyclophosphamide (44)  ·  venetoclax (43)  ·  fludarabine (39)  ·  Rituximab (33)  ·  fludarabine phosphate (26)  ·  Decitabine (16)  ·  Filgrastim (16)  ·  Lenalidomide (16)  ·  Dexamethasone (15)  ·  Methotrexate (15)  ·  Etoposide (14)  ·  Dasatinib (13)  ·  Mitoxantrone (12)

Sponsors

M.D. Anderson Cancer Center (44)  ·  National Cancer Institute (NCI) (41)  ·  Masonic Cancer Center, University of Minnesota (11)  ·  Novartis Pharmaceuticals (11)  ·  Gilead Sciences (10)  ·  Fred Hutchinson Cancer Center (9)  ·  AbbVie (8)  ·  Northwestern University (8)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8)  ·  Celgene (7)  ·  Amgen (6)  ·  Bristol-Myers Squibb (6)  ·  Incyte Corporation (6)  ·  Merck Sharp & Dohme LLC (6)  ·  Therapeutic Advances in Childhood Leukemia Consortium (6)

Countries

United States (456)  ·  Spain (53)  ·  France (50)  ·  Canada (40)  ·  Germany (37)  ·  Italy (36)  ·  Australia (30)  ·  China (24)  ·  Netherlands (22)  ·  United Kingdom (22)  ·  Belgium (17)  ·  Israel (15)  ·  Japan (13)  ·  South Korea (13)  ·  Poland (11)

Top investigators

Roger Strair, MD, PhD (4)  ·  Farhad Ravandi-Kashani, MD (3)  ·  Abhinav Deol, M.D. (2)  ·  Ajay Gopal (2)

Results publications

PMID 31527168, PMID 33197925, PMID 34398557, PMID 36841672, PMID 17151364, PMID 19010875, PMID 19029442, PMID 19139736, PMID 19503090, PMID 20460644, PMID 20563869, PMID 21145590, PMID 21494838, PMID 22080968, PMID 22448921, PMID 22987312, PMID 23092873, PMID 23233571, PMID 23256542, PMID 23393050, PMID 23400739, PMID 23887852, PMID 24200998, PMID 24241210, PMID 24276047, PMID 24355079, PMID 24615776, PMID 24615777, PMID 24615778, PMID 25441108, PMID 26472751, PMID 27118540, PMID 27544076, PMID 28161120, PMID 28280089, PMID 29042364, PMID 29141948, PMID 29142066, PMID 29296751, PMID 29296805, PMID 29339097, PMID 29432154, PMID 29610115, PMID 30361262, PMID 30444200, PMID 30559424, PMID 30962222, PMID 31235963, PMID 31443741, PMID 31471376

NIH funding

2018 (11), 2017 (8), 2023 (8), 2019 (6), U01CA076576 (6), 2014 (5), 2015 (4), P30CA015083 (4), P30CA015704 (4), P30CA016672 (4), P30CA072720 (4), 2016 (3), P01CA018029 (3), P30CA006973 (3), P30CA016058 (3)